Skip to content

Phase I stduy of natural killer (NK) cells treating acute leukemia

Phase I stduy of natural killer (NK) cells treating acute leukemia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OON-17012093
Enrollment
Unknown
Registered
2017-07-23
Start date
2017-07-21
Completion date
Unknown
Last updated
2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute leukemia

Interventions

the NK therapy group:Chemotherapy and NK therapy group

Sponsors

Hebei Yanda Ludaopei Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 70 Years

Inclusion criteria

Inclusion criteria: The patients diagnosed with low or intermediate risk of acute leukemia who obtained the first complete remission (CR) after chemotherapy and continuous complete remission (CCR)=4 months.(the United States NCCN 2015.2 standard); The patients who experienced the last chemotherapy or total body irradiation= 2 weeks; Hb=80g/L, WBC=2.5×10^9/L and PLT=50×10^9/L; Aged 2 to 70 Years; Patients with self-knowledge ability can sign the consent form; Patients or the clients authorized by patients sign the consent form, or pediatric patients' legal guardians sign the consent form and are voluntary to participate in the clinical trials.

Exclusion criteria

Exclusion criteria: Intracranial hypertension or unconsciousness; Symptomatic heart failure or severe cardiac arrhythmia; Respiratory failure; Patients with other types of malignancy; T cell acute lymphocytic leukemia; Disseminated intravascular coagulation; Serum creatinine and/or urea nitrogen=1.5 ×normal; Serum total bilirubin=1.5 ×normal; Sepsis or other uncontrolled active infection;Uncontrolled diabetes;Severe mental disorder; WHO physical status classification level=3; Allergic to IL2; Organ transplant recipients; Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
The effective rate of minimal residual disease;The ratio of 2 years-continued complete remission;

Countries

China

Contacts

Public ContactPeihua Lu

Hebei Yanda Ludaopei Hospital

peihua_lu@126.com+86 18611636171

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026